Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan

Oncotarget

Volumn 5, Issue 9, 2014, Pages 2807-2819

  Maitra, Radhashree ^a   Seetharam, Raviraja ^a   Tesfa, Lydia ^b   Augustine, Titto A ^b   Klampfer, Lidija ^a,b,e   Coffey, Matthew C ^c   Mariadason, John M ^d   Goel, Sanjay ^a,b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c ONCOLYTICS BIOTECH INC   (Canada)

^d OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^e SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Apoptosis; Caspase3; Colorectal cancer; p21; Reovirus

Indexed keywords

CASPASE 3; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; ONCOLYTIC VIRUS; PROTEIN P21; PROTEIN P53; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

APOPTOSIS; ARTICLE; CELL GROWTH; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; GROWTH INHIBITION; NONHUMAN; ONCOGENE K RAS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN INDUCTION; REOVIRUS; VIRAL GENE DELIVERY SYSTEM; ANALOGS AND DERIVATIVES; ANIMAL; CELL CYCLE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; GENETICS; HUMAN; MULTIMODALITY CANCER THERAPY; MUTATION; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PHYSIOLOGY; RAT; REOVIRIDAE; SCANNING ELECTRON MICROSCOPY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CAMPTOTHECIN; CELL CYCLE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DRUG SYNERGISM; HUMANS; MICROSCOPY, ELECTRON, SCANNING; MUTATION; ONCOLYTIC VIROTHERAPY; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RATS; REOVIRIDAE; TUMOR CELLS, CULTURED;

EID: 84901236048     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1921     Document Type: Article

References (34)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62(4):220-241.
2. East JE and Dekker E. Colorectal cancer diagnosis in 2012: A new focus for CRC prevention-more serration, less inflammation. Nat Rev Gastroenterol Hepatol. 2013.
3. Sei S, Mussio JK, Yang QE, Nagashima K, Parchment RE, Coffey MC, Shoemaker RH and Tomaszewski JE. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer. 2009; 8:47.
4. Shmulevitz M, Marcato P and Lee PW. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Oncogene. 2005; 24(52):7720-7728.
5. Marcato P, Shmulevitz M and Lee PW. Connecting reovirus oncolysis and Ras signaling. Cell Cycle. 2005; 4(4):556-559.
6. Strong JE, Coffey MC, Tang D, Sabinin P and Lee PW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 1998; 17(12):3351-3362.
7. Coffey MC, Strong JE, Forsyth PA and Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science. 1998; 282(5392):1332-1334.
8. Knowlton JJ, Dermody TS and Holm GH. Apoptosis induced by mammalian reovirus is beta interferon (IFN) independent and enhanced by IFN regulatory factor 3- and NF-kappaB-dependent expression of Noxa. J Virol. 2012; 86(3):1650-1660.
9. Beckham JD, Tuttle KD and Tyler KL. Caspase-3 activation is required for reovirus-induced encephalitis in vivo. J Neurovirol. 2010; 16(4):306-317.
10. Twigger K, Roulstone V, Kyula J, Karapanagiotou EM, Syrigos KN, Morgan R, White C, Bhide S, Nuovo G, Coffey M, Thompson B, Jebar A, Errington F, Melcher AA, Vile RG, Pandha HS, et al. Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer. 2012; 12:368.
11. Maitra R, Ghalib MH and Goel S. Reovirus: a targeted therapeutic--progress and potential. Mol Cancer Res. 2012; 10(12):1514-1525.
12. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F and Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006; 66(8):3992-3995.
13. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008; 26(3):374-379.
14. Norman KL and Lee PW. Reovirus as a novel oncolytic agent. J Clin Invest. 2000; 105(8):1035-1038.
15. Shirasawa S, Furuse M, Yokoyama N and Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science. 1993; 260(5104):85-88.
16. Roulstone V, Twigger K, Zaidi S, Pencavel T, Kyula JN, White C, McLaughlin M, Seth R, Karapanagiotou EM, Mansfield D, Coffey M, Nuovo G, Vile RG, Pandha HS, Melcher AA and Harrington KJ. Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy. Gene Ther. 2012; 20(5):521-528.
17. Berger AK and Danthi P. Reovirus activates a caspase-independent cell death pathway. MBio. 2013; 4(3):e00178-00113.
18. Gravitz L. Chemoprevention: First line of defence. Nature. 2011; 471(7339):S5-7.
19. O'Dwyer PJ and Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol. 2006; 24(28):4534-4538.
20. Motwani M, Jung C, Sirotnak FM, She Y, Shah MA, Gonen M and Schwartz GK. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res. 2001; 7(12):4209-4219.
21. Zhang Y, Fujita N and Tsuruo T. Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene. 1999; 18(5):1131-1138.
22. Gartel AL and Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther. 2002; 1(8):639-649.
23. Ando T, Kawabe T, Ohara H, Ducommun B, Itoh M and Okamoto T. Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage. J Biol Chem. 2001; 276(46):42971-42977.
24. Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F, Coffey M, Harrington KJ and Morgan R. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res. 2009; 15(19):6158-6166.
25. Heinemann L, Simpson GR, Boxall A, Kottke T, Relph KL, Vile R, Melcher A, Prestwich R, Harrington KJ, Morgan R and Pandha HS. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer. 2011; 11:221.
26. Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M, Thompson B, Vile RG, Heinemann L, Pandha HS, Errington F, Melcher AA and Harrington KJ. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res. 2008; 14(3):912-923.
27. Gollamudi R, Ghalib MH, Desai KK, Chaudhary I, Wong B, Einstein M, Coffey M, Gill GM, Mettinger K, Mariadason JM, Mani S and Goel S. Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs. 2010; 28(5):641-649.
28. http://clinicaltrials.gov/ct2/show/NCT01274624?term=reovirus+irinotecan&rank=1. 2013; Accessed Jul 6, 2013.
29. Allyson J. Ocean TSB-S, Imran Chaudhary, Romae Palmer, Paul J. Christos, Alice Mercado, Erika O. Florendo, Veronica A. Rosales, Joseph T. Ruggiero, Elizabeta C. Popa, Melissa Wilson, Mohammad Haroon Ghalib, Yijuan Hou, Umang Shah, Lakshmi Rajdev, Tarek Elrafei, George M. Gill, Matthew C. Coffey, Manish A. Shah, Sanjay Goel. A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant KRAS-mutant metastatic colorectal cancer (mCRC). J Clin Oncol. 2012; 30(suppl 34; abstr 450).
30. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, von Moos R, Vieitez JM, Bouche O, Borg C, Steffens CC, Alonso-Orduna V, Schlichting C, Reyes-Rivera I, Bendahmane B, Andre T, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013; 14(1):29-37.
31. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R and Allegra C. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012; 30(28):3499-3506.
32. Sheng H, Shao J and Dubois RN. K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1. Cancer Res. 2001; 61(6):2670-2675.
33. Mariadason JM, Rickard KL, Barkla DH, Augenlicht LH and Gibson PR. Divergent phenotypic patterns and commitment to apoptosis of Caco-2 cells during spontaneous and butyrate-induced differentiation. J Cell Physiol. 2000; 183(3):347-354.
34. Chou TC and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55.